1 |
Gentile V, Davies PJ and Baldini A (1994) The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics 20, 295-297
DOI
|
2 |
Fesus L and Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27, 534-539
DOI
|
3 |
Fraij BM and Gonzales RA (1997) Organization and structure of the human tissue transglutaminase gene. Biochim Biophys Acta 1354, 65-71
DOI
|
4 |
Kiraly R, Demeny M and Fesus L (2011) Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J 278, 4717-4739
DOI
|
5 |
Shrestha R, Tatsukawa H, Shrestha R et al (2015) Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis 6, e2002
DOI
|
6 |
Murthy SN, Iismaa S, Begg G, Freymann DM, Graham RM and Lorand L (2002) Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity. Proc Natl Acad Sci U S A 99, 2738-2742
DOI
|
7 |
Lee KN, Arnold SA, Birckbichler PJ et al (1993) Sitedirected mutagenesis of human tissue transglutaminase: Cys-277 is essential for transglutaminase activity but not for GTPase activity. Biochim Biophys Acta 1202, 1-6
DOI
|
8 |
Yee VC, Le Trong I, Bishop PD, Pedersen LC, Stenkamp RE and Teller DC (1996) Structure and function studies of factor XIIIa by x-ray crystallography. Semin Thromb Hemost 22, 377-384
DOI
|
9 |
Pinkas DM, Strop P, Brunger AT and Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5, e327
DOI
|
10 |
Kuo TF, Tatsukawa H and Kojima S (2011) New insights into the functions and localization of nuclear transglutaminase 2. FEBS J 278, 4756-4767
DOI
|
11 |
Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C and Sollid LM (2010) Redox regulation of transglutaminase 2 activity. J Biol Chem 285, 25402-25409
DOI
|
12 |
Milakovic T, Tucholski J, McCoy E and Johnson GV (2004) Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 279, 8715-8722
DOI
|
13 |
Malorni W, Farrace MG, Matarrese P et al (2009) The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrialdependent apoptosis. Cell Death Differ 16, 1480-1492
DOI
|
14 |
Stephens P, Grenard P, Aeschlimann P et al (2004) Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci 117, 3389-3403
DOI
|
15 |
Mhaouty-Kodja S (2004) Ghalpha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 96, 363-367
DOI
|
16 |
Dupuis M, Levy A and Mhaouty-Kodja S (2004) Functional coupling of rat myometrial alpha 1-adrenergic receptors to Gh alpha/tissue transglutaminase 2 during pregnancy. J Biol Chem 279, 19257-19263
DOI
|
17 |
DiRaimondo TR, Plugis NM, Jin X and Khosla C (2013) Selective inhibition of extracellular thioredoxin by asymmetric disulfides. J Med Chem 56, 1301-1310
DOI
|
18 |
Shin DM, Jeon JH, Kim CW et al (2008) TGFbeta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J 22, 2498-2507
DOI
|
19 |
Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM and Iismaa SE (2006) Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity. J Biol Chem 281, 12603-12609
DOI
|
20 |
Gibrat C, Bousquet M, Saint-Pierre M et al (2010) Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry 34, 193-203
DOI
|
21 |
Tremblay ME, Saint-Pierre M, Bourhis E, Levesque D, Rouillard C and Cicchetti F (2006) Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 27, 862-870
DOI
|
22 |
Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548
DOI
|
23 |
Zainelli GM, Ross CA, Troncoso JC, Fitzgerald JK and Mumna NA (2004) Calmodulin regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci 24, 1954-1961
DOI
|
24 |
Mastroberardino PG, Iannicola C, Nardacci R et al (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9, 873-880
DOI
|
25 |
Bailey CD and Johnson GV (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregateindependent mechanisms. J Neurochem 92, 83-92
DOI
|
26 |
Sun L, Xu S, Zhou M, Wang C, Wu Y and Chan P (2010) Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Brain Res 1335, 74-82
DOI
|
27 |
Fabbi M, Marimpietri D, Martini S et al (1999) Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ. 6, 992-1001
DOI
|
28 |
Min B, Park H, Lee S et al (2016) CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer. Oncogene 35, 3718-3728
DOI
|
29 |
Luciani A, Villella VR, Vasaturo A et al (2009) SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 183, 2775-2784
DOI
|
30 |
Ku BM, Kim DS, Kim KH et al (2013) Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J 27, 3487-3495
DOI
|
31 |
Norlund MA, Lee JM, Zainelli GM and Muma NA (1999) Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res 851, 154-163
DOI
|
32 |
Johnson GV, Cox TM, Lockhart JP, Zinnerman MD, Miller ML and Powers RE (1997) Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 751, 323-329
DOI
|
33 |
Shinagawa R, Masuda S, Sasaki R, Ikura K and Takahata K (1997) In vitro neurotoxicity of amyloid beta-peptide cross-linked by transglutaminase. Cytotechnology 23, 77-85
DOI
|
34 |
Curro M, Ferlazzo N, Condello S, Caccamo D and Lentile R (2010) Transglutaminase 2 silencing reduced the beta-amyloid-effects on the activation of human THP-1 cells. Amino Acids 39, 1427-1433
DOI
|
35 |
Hartley DM, Zhao C, Speier AC et al (2008) Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem 283, 16790-16800
DOI
|
36 |
Boros S, Kamps B, Wunderink L, de Bruijn W, de Jong WW and Boelens WC (2004) Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta. FEBS Lett 576, 57-62
DOI
|
37 |
Wang X, Sarkar A, Cicchetti F et al (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 231, 57-66
DOI
|
38 |
Sung K, Kamiya N, Kawata N, Kamiya S and Goto M (2010) Functional glass surface displaying a glutamyl donor substrate for transglutaminase-mediated protein immobilization. Biotechnol J 5, 456-462
DOI
|
39 |
Karpuj MV, Becher MW, Springer JE et al (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8, 143-149
DOI
|
40 |
Dedeoglu A, Kubilus JK, Jeitner TM et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22, 8942-8950
DOI
|
41 |
Case A, Ni J, Yeh LA and Stein RL (2005) Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors. Anal Biochem 338, 237-244
DOI
|
42 |
Zhang W, Johnson BR and Bjornsson TD (1997) Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Life Sci 60, 2323-2332
DOI
|
43 |
Zemaitaitis MO, Lee JM, Troncoso JC and Muma NA (2000) Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol 59, 983-989
DOI
|
44 |
Tucholski J, Kuret J and Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 73, 1871-1880
|
45 |
Halverson RA, Lewis J, Frausto S, Hutton M and Muma NA (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25, 1226-1233
DOI
|
46 |
Lin MK and Farrer MJ (2014) Genetics and genomics of Parkinson's disease. Genome Med 6, 48
DOI
|
47 |
Kalia LV and Lang AE (2015) Parkinson's disease. Lancet 386, 896-912
DOI
|
48 |
de Jager M, van der Wildt B, Schul E et al (2013) Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy. Neurobiol Aging 34, 1159-1169
DOI
|
49 |
Wilhelmus MM, Verhaar R, Andringa G et al (2011) Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol 21, 130-139
DOI
|
50 |
Mehta K (2005) Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 38, 1-18
|
51 |
Chai C and Lim KL (2013) Genetic insights into sporadic Parkinson's disease pathogenesis. Curr Genomics 14, 486-501
|
52 |
Beck KE, De Girolamo LA, Griffin M and Billett EE (2006) The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells. Neurosci Lett 405, 46-51
DOI
|
53 |
Verhaar R, Jongenelen CA, Gerard M et al (2011) Blockade of enzyme activity inhibits tissue transglutaminasemediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem Int 58, 785-793
DOI
|
54 |
Junn E, Ronchetti RD, Quezado MM, Kim SY and Mouradian MM (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100, 2047-2052
DOI
|
55 |
Schmid AW, Chiappe D, Pignat V et al (2009) Dissecting the mechanisms of tissue transglutaminase-induced crosslinking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. J Biol Chem 284, 13128-13142
DOI
|
56 |
Sato H, Arawaka S, Hara S et al (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31, 16884-16894
DOI
|
57 |
Min B, Kwon YC, Choe KM and Chung KC (2015) PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation. J Neurosci Res 93, 722-735
DOI
|
58 |
Grenard P, Bates MK and Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 276, 33066-33078
DOI
|
59 |
Park D, Choi SS and Ha KS (2010) Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 39, 619-631
DOI
|
60 |
Sarkar NK, Clarke DD and Waelsch H (1957) An enzymically catalyzed incorporation of amines into proteins. Biochim Biophys Acta 25, 451-452
DOI
|
61 |
Achyuthan KE and Greenberg CS (1987) Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262, 1901-1906
|
62 |
Nakaoka H, Perez DM, Baek KJ et al (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264, 1593-1596
DOI
|
63 |
Hasegawa G, Suwa M, Ichikawa Y et al (2003) A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373, 793-803
DOI
|
64 |
Jones RA, Nicholas B, Mian S, Davies PJ and Griffin M (1997) Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci 110, 2461-2472
|
65 |
Mishra S and Murphy LJ (2006) The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 339, 726-730
DOI
|
66 |
Takeuchi Y, Ohashi H, Birckbichler PJ and Ikejima T (1998) Nuclear translocation of tissue type transglutaminase during sphingosine-induced cell death: a novel aspect of the enzyme with DNA hydrolytic activity. Z Naturforsch C 53, 352-358
|
67 |
Verhaar R, Drukarch B, Bol JG, Jongenelen CA, Musters RJ and Wilhelmus MM (2012) Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease. Neurobiol Dis 45, 839-850
DOI
|
68 |
Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55, 259-272
DOI
|
69 |
Mishra S and Murphy LJ (2004) Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279, 23863-23868
DOI
|
70 |
Lorand L and Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4, 140-156
DOI
|
71 |
Nurminskaya MV and Belkin AM (2012) Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 294, 1-97
|
72 |
Esposito C and Caputo I (2005) Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J 272, 615-631
DOI
|
73 |
Lesort M, Tucholski J, Miller ML and Johnson GV (2000) Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol 61, 439-463
DOI
|
74 |
Dieterich W, Ehnis T, Bauer M et al (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3, 797-801
DOI
|
75 |
Sollid LM, Molberg O, McAdam S and Lundin KE (1997) Autoantibodies in coeliac disease: tissue transglutaminase--guilt by association? Gut 41, 851-852
DOI
|
76 |
Birckbichler PJ, Orr GR, Conway E and Patterson MK (1977) Transglutaminase activity in normal and transformed cells. Cancer Res 37, 1340-1344
|
77 |
Griffin M, Smith LL and Wynne J (1979) Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat. Br J Exp Pathol 60, 653-661
|